<DOC>
	<DOCNO>NCT02411695</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics ( PK ) oral brexpipirazole adolescent subject schizophrenia Other Related Psychiatric Disorders .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability Pharmacokinetics Oral Brexpiprazole ( OPC- 34712 ) Adolescents With Schizophrenia</brief_title>
	<detailed_description>Schizophrenia severely delibitating mental illness affect approximately 1 % world population . The onset schizophrenia symptom typically peak late adolescence early adulthood . In minority case , initial episode may occur childhood early adolescence . Patients experience `` early-onset schizophrenia '' exhibit symptom severe follow chronic course ; adolescent schizophrenia may never achieve full remission initial episode . The prognosis early-onset schizophrenia tend poor , cognitive impairment great compare individual whose onset schizophrenia occur later life . Several antipsychotic investigate treatment adolescent schizophrenia , however , particular challenge develop body sensitive side effect antipsychotic , particularly respect weight gain . In order enroll population include young age , adolescent related psychiatric disorder also include study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>Male female subject 13 17 year age , inclusive , time informed consent . Subjects current diagnosis primary schizophrenia spectrum bipolar spectrum disorder , define DSMIVTR criterion , confirm KSADSPL . No psychiatric hospitalization within past 12 week . Subjects require treatment antipsychotic medication . Subjects receive previous outpatient antipsychotic treatment adequate dose adequate duration ( least 6 week ) show previous good response antipsychotic treatment ( clozapine ) last 12 month . Subjects body weight Screening great equal 30 kg . Sexually active female childbearing potential male subject practice two different method birth control partner ( abstinence ) trial 30 day last dose trial medication Females breastfeed and/or positive pregnancy test result prior receive trial drug . Subjects receive continuous medication therapy treat schizophrenia schizophrenia spectrum diagnosis less six month prior first dose study medication AND subject receive continuous medication therapy treat bipolar bipolar spectrum disorder less two month past three year ; subject require one antipsychotic.. Subjects current DSMIVTR diagnosis schizophrenia spectrum , bipolar spectrum , include Axis I Axis II ( DSMIVTR ) disorder . Subjects clinical presentation and/or history neurodevelopmental disorder Subjects meet DSMIVTR criterion substance abuse dependence within past 180 day . Subjects currently clinically significant neurological , hepatic , renal , metabolic , hematological , immunological , cardiovascular , pulmonary , gastrointestinal disorder history myocardial infarction , congestive heart failure , HIV seropositive status/acquired immunodeficiency syndrome , chronic hepatitis B C. Subjects IDDM ( ie , subject use insulin ) exclude . Subjects nonIDDM may eligible trial condition stable . Subjects epilepsy history seizure . Any major surgery blood transfusion within 30 day prior first dose trial medication . Subjects positive drug screen cocaine illicit drug , alcohol exclude may retested rescreened . Prohibited concomitant medication use within exclusionary period prior Day 1 Dose Escalation Phase anticipate need medication trial . Subjects participate clinical trial expose IMP within last 30 day participate two interventional clinical trial within past year . Subjects history true allergic response ( ie , intolerance ) one class medication . Inability tolerate oral medication swallow tablet .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adolescent</keyword>
	<keyword>Otsuka ,</keyword>
	<keyword>Brexpiprazole</keyword>
</DOC>